Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E-DIS2: Pursuing vs Interrupting Chemotherapy in Metastatic Esophageal Squamous-cell Cancer
NCT03301454Phase 2Terminated
- Sponsor
- Centre Oscar Lambret
- Start
- Aug 2018
- Primary completion
- Jul 2022
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of paclitaxel, fluorouracil, levoleucovorin in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Centre Oscar Lambret. Started Aug 2018; status: terminated.
02
Drugs
paclitaxelfluorouracillevoleucovorin
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT03301454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03301454.